Navigation Links
Ovarian transplantation: First baby is born after a new technique
Date:6/29/2009

Amsterdam, The Netherlands: A new technique for transplanting the ovaries of women who have lost their fertility as a result of cancer treatment was outlined to the 25th annual conference of the European Society of Human Reproduction and Embryology today (Monday 29 June). Dr. Pascal Piver, manager of the IVF Centre at Limoges University Hospital, Limoges, France, described a new, two-step method of ovarian transplant that has produced excellent results in women whose ovaries have been frozen because of cancer treatment. He said that his team's technique worked to restore ovarian function quickly and already one patient from his clinic had had a baby and another had become pregnant.

"On June 22, a baby girl was born to a mother who had been menopausal for two years as a result of treatment for sickle cell anaemia. After transplanting her own ovarian tissue she started ovulating in four months and became pregnant naturally six months after transplantation. Both mother and baby are doing well", he said.

Dr. Piver and colleagues set out to tackle one of the biggest problems of ovarian transplantation: the low response to stimulation caused by insufficient vascularisation of the transplanted tissue.

"In order for a woman to become pregnant, the ovaries need to be responsive to the action of hormones that cause them to release eggs each month," he explained. "If the blood supply to the ovaries is insufficient, this will not happen, even though the transplant may look as though it has been successful."

To overcome this problem they carried out a two-stage procedure, first grafting small pieces of the frozen ovarian tissue in the ovarian and peritoneal areas three days before the real transplant. The first graft encourages the growth of blood vessels and paves the way for the ovary to become fully functioning in a shorter time scale than would be possible if all the tissue were to be transplanted at the same time.

The
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
European Society for Human Reproduction and Embryology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Mutation of the COX2 gene can double or treble a womans risk of ovarian cancer
2. Ovarian cancer stem cells identified, characterized
3. Oocyte-specific gene mutations cause premature ovarian failure
4. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
5. Promising new treatment option for women with recurrent ovarian cancer
6. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
7. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
8. Which came first, the moth or the cactus?
9. First all-African GM crop is resistant to maize streak virus
10. Scientists retrace evolution with first atomic structure of an ancient protein
11. CU-Boulder team discovers first ancient manioc fields in Americas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... 2, 2014 Best-selling author Sam Kean stops by ... Megalodon, the 50-foot super shark that, despite what "Shark ... Learn all about it at http://youtu.be/KhFygIoW_MA . , ... of Madness, Love and the History of the World ... the Reactions treatment in a 10-episode video series produced ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... The apparently random self-assembly of molecular threads into the ... frantic than previously thought, Michigan State University scientists say. ... the nature of some diseases. How proteins spontaneously ... wide variety of functional or malfunctioning three-dimensional ...
... A phylogenetic analysis can take a long time to ... efficiently and effectively. The National Institute for Mathematical and ... focusing on high performance computing (HPC) for phylogenetics. ... to use TeraGrid, the CIPRES Portal, the iPlant Discovery ...
... The American Physical Society (APS) announces a new public ... public libraries in the United States full use of ... back to the first issue in 1893, a collection ... provide this access at no cost to participating public ...
Cached Biology News:Scientists post lower speed limit for cell-signaling protein assembly 2
(Date:9/2/2014)... be used for detailed studies of what happens on ... pharmaceuticals research, among other applications. A group of researchers ... artificial cell membranes form across a large number of ... between the interior of a cell and its surroundings ... a surface layer that holds the cell together and ...
(Date:9/2/2014)... 2014 Persistence Market Research ( ... Pharmaceutical, Biopharma and Life Sciences: North America ... membrane technology market for pharmaceutical, biopharma and life sciences is ... expected to grow at a CAGR of 9.1% from ... USD 10,886.0 million in 2019. Browse the ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... release is available in German . ... with microelectronic components gradually being replaced by nanoelectronic ... the present stage the most commonly used material ... further miniaturization and technological progress. New electronic materials ...
... Rosei of the INRS Energy Materials Telecommunications Center has ... Friedrich Wilhelm Bessel Research Award given by the Alexander ... awards annually to young, high level researchers around the ... caliber and scope of his research in the field ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported financial and operational results for the ... For the third quarter of 2010, PharmAthene ... in the same period of 2009.  For the nine ...
Cached Biology Technology:Step by step toward tomorrow's nanomaterial 2INRS professor Federico Rosei receives a 2010 Friedrich Wilhelm Bessel Research Award 2PharmAthene Reports Third Quarter 2010 Financial and Operational Results 2PharmAthene Reports Third Quarter 2010 Financial and Operational Results 3PharmAthene Reports Third Quarter 2010 Financial and Operational Results 4PharmAthene Reports Third Quarter 2010 Financial and Operational Results 5PharmAthene Reports Third Quarter 2010 Financial and Operational Results 6PharmAthene Reports Third Quarter 2010 Financial and Operational Results 7
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: